Analysts Issue Forecasts for Collegium Pharmaceutical Inc’s Q1 2018 Earnings (COLL)

Collegium Pharmaceutical Inc (NASDAQ:COLL) – Analysts at Jefferies Group issued their Q1 2018 EPS estimates for Collegium Pharmaceutical in a report released on Thursday. Jefferies Group analyst D. Steinberg expects that the specialty pharmaceutical company will post earnings of ($0.23) per share for the quarter. Jefferies Group has a “Buy” rating and a $32.00 price objective on the stock. Jefferies Group also issued estimates for Collegium Pharmaceutical’s FY2018 earnings at ($0.41) EPS, FY2019 earnings at $0.42 EPS, FY2020 earnings at $1.09 EPS and FY2021 earnings at $1.61 EPS.

How to Become a New Pot Stock Millionaire

Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings data on Wednesday, March 7th. The specialty pharmaceutical company reported ($0.54) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.56) by $0.02. The business had revenue of $10.79 million for the quarter, compared to analysts’ expectations of $9.88 million. Collegium Pharmaceutical had a negative return on equity of 73.00% and a negative net margin of 262.91%. The firm’s revenue for the quarter was up 728.4% compared to the same quarter last year.

Other equities analysts also recently issued research reports about the company. Piper Jaffray Companies set a $33.00 price objective on Collegium Pharmaceutical and gave the company a “buy” rating in a research report on Tuesday, January 23rd. BidaskClub downgraded Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, January 9th. Needham & Company LLC upped their price objective on Collegium Pharmaceutical from $25.00 to $28.00 and gave the company a “buy” rating in a research report on Tuesday, December 5th. They noted that the move was a valuation call. HC Wainwright reaffirmed a “buy” rating and issued a $21.00 price objective on shares of Collegium Pharmaceutical in a research report on Friday, November 17th. Finally, Janney Montgomery Scott set a $26.00 price objective on Collegium Pharmaceutical and gave the company a “buy” rating in a research report on Tuesday, February 6th. One analyst has rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $29.17.

Collegium Pharmaceutical (NASDAQ:COLL) opened at $27.59 on Monday. Collegium Pharmaceutical has a 12-month low of $7.37 and a 12-month high of $29.90.

Several hedge funds have recently modified their holdings of the business. Citadel Advisors LLC lifted its stake in shares of Collegium Pharmaceutical by 773.8% during the 3rd quarter. Citadel Advisors LLC now owns 544,033 shares of the specialty pharmaceutical company’s stock worth $5,707,000 after purchasing an additional 481,771 shares during the last quarter. First Manhattan Co. purchased a new stake in shares of Collegium Pharmaceutical during the 4th quarter worth $8,606,000. Deutsche Bank AG lifted its stake in shares of Collegium Pharmaceutical by 528.0% during the 4th quarter. Deutsche Bank AG now owns 414,115 shares of the specialty pharmaceutical company’s stock worth $7,643,000 after purchasing an additional 348,169 shares during the last quarter. Cortina Asset Management LLC purchased a new stake in shares of Collegium Pharmaceutical during the 4th quarter worth $5,476,000. Finally, Macquarie Group Ltd. lifted its stake in shares of Collegium Pharmaceutical by 21.5% during the 4th quarter. Macquarie Group Ltd. now owns 1,616,117 shares of the specialty pharmaceutical company’s stock worth $29,833,000 after purchasing an additional 286,138 shares during the last quarter. Institutional investors and hedge funds own 87.60% of the company’s stock.

In other Collegium Pharmaceutical news, insider Alison B. Fleming sold 6,928 shares of the company’s stock in a transaction on Wednesday, January 10th. The stock was sold at an average price of $19.07, for a total value of $132,116.96. Following the completion of the sale, the insider now directly owns 32,651 shares in the company, valued at approximately $622,654.57. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Chairman Michael Thomas Heffernan sold 20,000 shares of the company’s stock in a transaction on Friday, January 19th. The stock was sold at an average price of $22.50, for a total value of $450,000.00. Following the completion of the sale, the chairman now owns 538,987 shares of the company’s stock, valued at $12,127,207.50. The disclosure for this sale can be found here. Insiders sold a total of 46,928 shares of company stock worth $1,082,317 in the last ninety days. 25.76% of the stock is currently owned by corporate insiders.

COPYRIGHT VIOLATION NOTICE: “Analysts Issue Forecasts for Collegium Pharmaceutical Inc’s Q1 2018 Earnings (COLL)” was first published by Markets Daily and is the property of of Markets Daily. If you are viewing this piece on another domain, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be accessed at https://www.themarketsdaily.com/2018/03/14/analysts-issue-forecasts-for-collegium-pharmaceutical-incs-q1-2018-earnings-coll.html.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.

Earnings History and Estimates for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply